publication date: Aug. 4, 2015
Phase II Trial Shows Benefit with Imbruvica in Activated B-cell-like Subtype of DLBCL
A phase II clinical trial identified patients with a specific molecular subtype of diffuse large B-cell lymphoma that are more likely to respond to Imbruvica (ibrutinib) treatment.
In the trial, patients with the activated B-cell-like subtype of DLBCL were more likely to respond to Imbruvica than patients with the germinal center B-cell-like subtype. The trial was jointly conducted by NCI and Pharmacyclics Inc., and was published in Nature Medicine.
The trial enrolled 80 patients with DLBCL that had relapsed or had not responded to prior treatment. All patients received Imbruvica. Tumor responses were seen in 25 percent of patients overall, including eight patients with complete responses and 12 with partial responses.
For the study population as a whole, after a median follow-up of 11.5 months, the median progression-free survival and overall survival were 1.6 and 6.4 months, respectively.
An analysis based on disease subtype showed that Imbruvica produced complete or partial responses in 37 percent (14 of 38) of patients with ABC DLBCL but only 5 percent of patients with GCB DLBCL.
The target for Imbruvica, Bruton’s tyrosine kinase, is a key component of B-cell receptor signaling. The new study provides the first clinical evidence that ABC but not GBC tumors may produce abnormal B-cell receptor signals that promote the survival of cancer cells by activating BTK, thereby accounting for the sensitivity of ABC tumors to Imbruvica.
“Clinical trials such as this are critical for translating basic molecular findings … Continue reading CCL July – Phase II Trial Shows Benefit with Imbruvica in Activated B-cell-like Subtype of DLBCL
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.